Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide Plus Vorinostat in Relapsed/Refractory AML
NCT01550224Phase 2Completed
- Start
- May 2013
- Primary completion
- Nov 2014
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide, vorinostat in acute myeloid leukemia (AML). Started May 2013; status: completed.
02
Drugs
temozolomidevorinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01550224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01550224.